# SUPPLEMENTAL SPECIALTY PA

# VECAMYL (mecamylamine hydrochloride)

#### POLICY

#### I. INDICATIONS

The indications below including FDA-approved indications and compendial uses are considered a covered benefit provided that all the approval criteria are met and the member has no exclusions to the prescribed therapy.

#### **FDA-Approved Indication**

Management of moderately severe to severe essential hypertension and in uncomplicated cases of malignant hypertension.

All other indications are considered experimental/investigational and not medically necessary.

## **II. CRITERIA FOR INITIAL APPROVAL**

#### A. Moderately severe to severe essential hypertension

Authorization of 12 months may be granted for moderately severe to severe essential hypertension when the member has had an inadequate response to a one month trial of a drug combination with at least 1 medication from each of the following classes unless the member has an intolerance or contraindication to the drug class:

- 1. Diuretic
- 2. Angiotensin-converting enzyme inhibitor or Angiotensin II receptor antagonist
- 3. Calcium channel blocker
- 4. Mineralocorticoid receptor antagonist (e.g., spironolactone)
- 5. Beta Blocker

#### B. Uncomplicated malignant hypertension

Authorization of 3 months may be granted for uncomplicated malignant hypertension when the member has had an inadequate response to a one month trial of a drug combination with at least 1 medication from each of the following classes unless the member has an intolerance or contraindication to the drug class:

- 1. Diuretic
- 2. Angiotensin-converting enzyme inhibitor or Angiotensin II receptor antagonist
- 3. Calcium channel blocker
- 4. Mineralocorticoid receptor antagonist (e.g., spironolactone)
- 5. Beta Blocker

### **III. REFERENCES**

- 1. Vecamyl [prescribing information]. New York, NY: Vyera Pharmaceuticals, LLC.; July 2018.
- 2. Carey RM, Calhoun DA, Bakris GL, et al. Resistant hypertension: Detection, evaluation, and management: A scientific statement from the American Heart Association. *Hypertension*. 2018;72:e53-e90.

Vecamyl 2992-A Supplemental Specialty PA P2023

© 2023 CVS Caremark. All rights reserved.

This document contains confidential and proprietary information of CVS Caremark and cannot be reproduced, distributed or printed without written permission from CVS Caremark. This document contains prescription brand name drugs that are trademarks or registered trademarks of pharmaceutical manufacturers that are not affiliated with CVS Caremark.

